CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
12
2021
accepted:
24
03
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- and Class II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) and membrane (M) proteins and others. This prospective COVID-19 Health Action Response for Marines (CHARM) study enabled assessment of T cell responses against S, N and M proteins in symptomatic and asymptomatic SARS-CoV-2 infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly and bimonthly for the next 6 weeks. Study participants who tested positive by qPCR SARS-CoV-2 test were enrolled in an immune response sub-study. FluoroSpot interferon-gamma (IFN-γ) and IL2 responses following qPCR-confirmed infection at enrollment (day 0), day 7 and 14 and more than 28 days later were measured using pools of 17mer peptides covering S, N, and M proteins, or CD4+CD8 peptide pools containing predicted epitopes from multiple SARS-CoV-2 antigens. Among 124 asymptomatic and 105 symptomatic participants, SARS-CoV-2 infection generated IFN-γ responses to the S, N and M proteins that persisted longer in asymptomatic cases. IFN-γ responses were significantly (p = 0.001) more frequent to the N pool (51.4%) than the M pool (18.9%) among asymptomatic but not symptomatic subjects. Asymptomatic IFN-γ responders to the CD4+CD8 pool responded more frequently to the S pool (55.6%) and N pool (57.1%), than the M pool (7.1%), but not symptomatic participants. The frequencies of IFN-γ responses to the S and N+M pools peaked 7 days after the positive qPCR test among asymptomatic (S pool: 22.2%; N+M pool: 28.7%) and symptomatic (S pool: 15.3%; N+M pool 21.9%) participants and dropped by >28 days. Magnitudes of post-infection IFN-γ and IL2 responses to the N+M pool were significantly correlated with IFN-γ and IL2 responses to the N and M pools. These data further support the central role of Th1-biased cell mediated immunity IFN-γ and IL2 responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-based COVID-19 vaccines that include the N and S proteins.
Identifiants
pubmed: 35390102
doi: 10.1371/journal.pone.0266691
pii: PONE-D-21-41021
pmc: PMC8989306
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Epitopes
0
Interleukin-2
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266691Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
PLoS One. 2021 Aug 20;16(8):e0256396
pubmed: 34415964
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
JCI Insight. 2017 Jan 12;2(1):e89154
pubmed: 28097230
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Clin Microbiol Infect. 2021 Jul;27(7):1029-1034
pubmed: 33813122
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
J Virol. 2020 Jun 16;94(13):
pubmed: 32546606
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
N Engl J Med. 2020 Dec 17;383(25):2407-2416
pubmed: 33176093
Sci Immunol. 2021 Mar 4;6(57):
pubmed: 33664060
PLoS One. 2013;8(2):e55571
pubmed: 23457473
Clin Microbiol Infect. 2021 Dec;27(12):1784-1789
pubmed: 34256141
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Cell Rep. 2021 Jul 20;36(3):109414
pubmed: 34260965
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
Cell Discov. 2021 Mar 25;7(1):18
pubmed: 33767156
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
PLoS One. 2021 Jan 25;16(1):e0245532
pubmed: 33493185
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Transl Med. 2021 Apr 21;13(590):
pubmed: 33723016
J Med Virol. 2022 Apr;94(4):1728-1733
pubmed: 34897752
PLoS One. 2021 Sep 8;16(9):e0256980
pubmed: 34495988
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Med. 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Science. 2021 Apr 30;:
pubmed: 33931567
JCI Insight. 2020 Oct 15;5(20):
pubmed: 32937615
J Clin Invest. 2021 Nov 1;131(21):
pubmed: 34720095
Immunity. 2021 May 11;54(5):1055-1065.e5
pubmed: 33945786
iScience. 2021 Feb 19;24(2):102096
pubmed: 33521593
Comput Struct Biotechnol J. 2021;19:518-529
pubmed: 33398234
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
Front Cell Infect Microbiol. 2020 Dec 18;10:605334
pubmed: 33392109
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
EBioMedicine. 2021 Jun;68:103401
pubmed: 34051441
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
J Immunol. 2021 Jul 15;207(2):376-379
pubmed: 34193597
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
Nat Immunol. 2022 Jan;23(1):50-61
pubmed: 34853448
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
NPJ Vaccines. 2021 May 13;6(1):74
pubmed: 33986272
Lancet Respir Med. 2021 Jul;9(7):712-720
pubmed: 33865504
PLoS One. 2014 Sep 11;9(9):e106241
pubmed: 25211344
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
J Exp Med. 2021 May 3;218(5):
pubmed: 33646265
Sci Adv. 2021 May 28;7(22):
pubmed: 34049881
Cell Rep. 2021 Sep 14;36(11):109708
pubmed: 34506741
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
Front Immunol. 2020 Oct 28;11:587615
pubmed: 33193414
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
bioRxiv. 2021 Mar 01;:
pubmed: 33688655
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Science. 2021 Mar 25;:
pubmed: 33766944
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Immunogenetics. 2013 Oct;65(10):711-24
pubmed: 23900783
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Vaccines (Basel). 2020 Jul 23;8(3):
pubmed: 32717854
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
Adv Drug Deliv Rev. 2021 Apr;171:29-47
pubmed: 33465451
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748